Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) focuses on commercializing cancer medicines, Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI)

Posted by Samantha Donahue May 24, 2013 0 Comment 1089 views


Ariad Pharmaceuticals, Inc (NASDAQ:ARIA): Thursday’s trading session saw Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) rising 5.48% and closed at $19.44. It opened at a price of $18.16 which touched an intraday high of $20.00, before moving down to close at $17.76 per share. In the previous day’s trading session, around 4.71 million shares were traded. This number was more than the average volume of 3.10 million that was measured over a 30-day period.

Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) is an international oncology company. It focuses on discovering, developing and commercializing medicines that are used in the treatment for cancer patients. Iclusig, ARIA’s first medicine, has been approved in the U.S for treating adult patients suffering from chronic, blast phase or accelerated chronic myeloid leukemia. This is intolerant or resistant to tyrosine kinase inhibitor (TKI) therapy that has been previously used. It is also used in the treatment of Philadelphia chromosome-positive acute-lymphoblastic leukemia. This leukemia may be intolerant or resistant to previous TKI therapy. As of 11 January 2013, new clinical trials of Iclusig in other forms of cancers were in progress.

Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI): Thursday’s trading session saw Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) rising 1.42% and closed at $8.55. It opened at a price of $8.35 which touched an intraday high of $8.60, before moving down to close at $8.27 per share. In the previous day’s trading session, around 0.774 million shares were traded. This number was more than the average volume of 0.952 million that was measured over a 30-day period.

SPPI is a bio-technology company. It has fully-integrated drug and commercial development operations. The company largely focuses on oncology and in hematology. In the U.S, Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) markets 3 oncology drugs, FOLOTYN, FUSILEV and ZEVALIN. It also markets ZEVALIN outside the U.S. Two of its drugs, apaziquone and belinostat are in late-stage development in addition to a diversified pipeline of other drug candidates. Apaziquone has been studied in 2, Phase III clinical-trials for treatment of non-muscle invasive bladder cancer. It is under strategic collaborations with Handok Pharmaceuticals Co. Ltd. (Handok) and Nippon Kayaku Co. Ltd (Nippon Kayaku). Belinostat is being studied in various indications.


About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment